Back to YMABY-mAbs Therapeutics, Inc. (YMAB)
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
Phase 2Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Neuroblastoma
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts